Biodexa Pharmaceuticals (BDRX) Competitors $3.71 -0.09 (-2.37%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$3.64 -0.08 (-2.02%) As of 02/21/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends BDRX vs. PCSA, PTIX, KTTA, SLXN, APVO, CDT, ERNA, PBLA, GLMD, and VRPXShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Processa Pharmaceuticals (PCSA), Protagenic Therapeutics (PTIX), Pasithea Therapeutics (KTTA), Silexion Therapeutics (SLXN), Aptevo Therapeutics (APVO), Conduit Pharmaceuticals (CDT), Eterna Therapeutics (ERNA), Panbela Therapeutics (PBLA), Galmed Pharmaceuticals (GLMD), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Processa Pharmaceuticals Protagenic Therapeutics Pasithea Therapeutics Silexion Therapeutics Aptevo Therapeutics Conduit Pharmaceuticals Eterna Therapeutics Panbela Therapeutics Galmed Pharmaceuticals Virpax Pharmaceuticals Processa Pharmaceuticals (NASDAQ:PCSA) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership. Do insiders & institutionals have more ownership in PCSA or BDRX? 91.9% of Processa Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 13.0% of Processa Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is PCSA or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Processa PharmaceuticalsN/A -195.21% -163.06% Biodexa Pharmaceuticals N/A N/A N/A Which has higher earnings and valuation, PCSA or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than Processa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcessa PharmaceuticalsN/AN/A-$11.12M-$3.39-0.16Biodexa Pharmaceuticals$83K5.32-$7.66MN/AN/A Which has more risk and volatility, PCSA or BDRX? Processa Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Does the media favor PCSA or BDRX? In the previous week, Processa Pharmaceuticals had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 1 mentions for Processa Pharmaceuticals and 0 mentions for Biodexa Pharmaceuticals. Processa Pharmaceuticals' average media sentiment score of 1.32 beat Biodexa Pharmaceuticals' score of 0.00 indicating that Processa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Processa Pharmaceuticals Positive Biodexa Pharmaceuticals Neutral Do analysts rate PCSA or BDRX? Processa Pharmaceuticals currently has a consensus price target of $6.00, suggesting a potential upside of 1,032.08%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Processa Pharmaceuticals is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor PCSA or BDRX? Processa Pharmaceuticals received 14 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 60.00% of users gave Processa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformProcessa PharmaceuticalsOutperform Votes1560.00% Underperform Votes1040.00% Biodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes SummaryProcessa Pharmaceuticals beats Biodexa Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$441,000.00$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / Sales5.32309.83453.2580.30Price / CashN/A67.8344.0437.47Price / Book0.096.747.634.64Net Income-$7.66M$138.11M$3.18B$245.69M7 Day Performance-13.11%-2.43%-1.91%-2.66%1 Month Performance-10.82%-1.91%-0.19%-2.15%1 Year PerformanceN/A-5.03%16.70%12.90% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.7148 of 5 stars$3.71-2.4%N/AN/A$138.87M$470,000.000.0020Gap DownPCSAProcessa Pharmaceuticals3.5999 of 5 stars$0.60-1.7%$6.00+898.3%-76.7%$1.97MN/A-0.1820PTIXProtagenic TherapeuticsN/A$0.27-2.5%N/A-73.7%$1.94MN/A-0.212KTTAPasithea Therapeutics0.7686 of 5 stars$1.45-0.7%N/A-82.7%$1.84MN/A0.003SLXNSilexion TherapeuticsN/A$1.08-15.0%$9.00+733.3%N/A$1.73MN/A0.00N/AAPVOAptevo Therapeutics1.9825 of 5 stars$3.34-8.2%$10,952.00+327,804.2%-100.0%$1.70M$3.11M0.0050Analyst RevisionNews CoverageHigh Trading VolumeCDTConduit PharmaceuticalsN/A$1.64+0.6%N/A-99.6%$1.69MN/A0.003ERNAEterna TherapeuticsN/A$0.31+6.7%N/A-80.4%$1.66M$70,000.00-0.0410Positive NewsGap UpPBLAPanbela TherapeuticsN/A$0.34+6.3%N/A-63.6%$1.65MN/A0.006GLMDGalmed Pharmaceuticals0.7082 of 5 stars$2.56+1.6%N/A-41.3%$1.64MN/A-0.1520VRPXVirpax Pharmaceuticals1.4411 of 5 stars$0.33+12.9%$3.00+819.4%-91.2%$1.60MN/A0.007Gap UpHigh Trading Volume Related Companies and Tools Related Companies Processa Pharmaceuticals Competitors Protagenic Therapeutics Competitors Pasithea Therapeutics Competitors Silexion Therapeutics Competitors Aptevo Therapeutics Competitors Conduit Pharmaceuticals Competitors Eterna Therapeutics Competitors Panbela Therapeutics Competitors Galmed Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDRX Stock Alerts